On the public citation graph
Sarcoma Immunotherapy: Past Approaches and Future Directions
0 signed · 181 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/(sici)1097-0215(19970926)73:1<42::aid-ijc8>3.0.co;2-1openalex-snapshot
Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides
inferredcites →https://doi.org/10.1002/(sici)1097-0215(19970926)73:1<50::aid-ijc9>3.0.co;2-0openalex-snapshot
Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens
inferredcites →https://doi.org/10.1002/1097-0142(197107)28:1<89::aid-cncr2820280117>3.0.co;2-qopenalex-snapshot
Occurrence of malignancy in immunodeficiency diseases: A literature review
inferredcites →https://doi.org/10.1002/1097-0142(19801001)46:7<1562::aid-cncr2820460711>3.0.co;2-9openalex-snapshot
Effect of human leukocyte interferon on the metastatic lung tumor of osteosarcoma. Case reports
inferredcites →https://doi.org/10.1002/1097-0142(19810515)47:10<2391::aid-cncr2820471012>3.0.co;2-bopenalex-snapshot
Conservative surgery and postoperative radiotherapy in 300 adults with soft-tissue sarcomas
inferredcites →https://doi.org/10.1002/1097-0142(19920801)70:3<633::aid-cncr2820700315>3.0.co;2-fopenalex-snapshot
Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas
inferredcites →https://doi.org/10.1002/1521-4141(200203)32:3<634::aid-immu634>3.0.co;2-9openalex-snapshot
PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2
inferredcites →https://doi.org/10.1002/bjs.1800830502openalex-snapshot
Management of soft tissue sarcoma
inferredcites →https://doi.org/10.1002/cncr.24566openalex-snapshot
Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma
inferredcites →https://doi.org/10.1002/cncr.27446openalex-snapshot
NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma
inferredcites →https://doi.org/10.1002/ijc.1282openalex-snapshot
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues
inferredcites →https://doi.org/10.1002/ijc.1451openalex-snapshot
Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen ny-eso-1 but not mage-a1 or ct7
inferredcites →https://doi.org/10.1002/ijc.24439openalex-snapshot
Cancer incidence and risk factors after solid organ transplantation
inferredcites →https://doi.org/10.1002/ijc.24461openalex-snapshot
A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25 hi FoxP3+) in Ewing sarcoma patients is associated with metastatic disease
inferredcites →https://doi.org/10.1002/ijc.2910530407openalex-snapshot
Ganglioside expression on human malignant melanoma assessed by quantitative immune thin‐layer chromatography
inferredcites →https://doi.org/10.1002/path.2819openalex-snapshot
Pro‐inflammatory chemokine–chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8+ T‐lymphocyte infiltration and affect tumour progression
inferredcites →https://doi.org/10.1002/pbc.24686openalex-snapshot
Mifamurtide in metastatic and recurrent osteosarcoma: A patient access study with pharmacokinetic, pharmacodynamic, and safety assessments
inferredcites →https://doi.org/10.1007/978-1-4614-4732-0_1openalex-snapshot
Historical Perspectives and Current Trends in Cancer Immunotherapy
inferredcites →https://doi.org/10.1007/978-1-4614-4732-0_7openalex-snapshot
Cytokines in the Treatment of Cancer
inferredcites →https://doi.org/10.1007/978-3-642-81332-0_7openalex-snapshot
Adjuvant Interferon Treatment of Human Osteosarcoma
inferredcites →https://doi.org/10.1007/bf00199995openalex-snapshot
Induction of lymphokine-activated killer cytotoxicity with interleukin-2 and tumor necrosis factor-? against primary lung cancer targets
inferredcites →https://doi.org/10.1016/0163-7258(94)90023-xopenalex-snapshot
Coley's toxins, tumor necrosis factor and cancer research: A historical perspective
inferredcites →https://doi.org/10.1016/j.cell.2011.02.013openalex-snapshot
Hallmarks of Cancer: The Next Generation
inferredcites →https://doi.org/10.1016/j.coi.2006.01.011openalex-snapshot
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
inferredcites →https://doi.org/10.1016/j.ejca.2008.10.026openalex-snapshot
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
inferredcites →https://doi.org/10.1016/j.febslet.2013.10.015openalex-snapshot
Checkpoint blocking antibodies in cancer immunotherapy
inferredcites →https://doi.org/10.1016/j.suronc.2006.05.002openalex-snapshot
Lessons from Coley's Toxin
inferredcites →https://doi.org/10.1016/s0092-8674(05)80055-8openalex-snapshot
Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy
inferredcites →https://doi.org/10.1016/s1470-2045(09)70334-1openalex-snapshot
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
inferredcites →https://doi.org/10.1016/s1470-2045(12)70582-xopenalex-snapshot
Cytokine patterns in patients with cancer: a systematic review
inferredcites →https://doi.org/10.1016/s1471-4906(01)01888-9openalex-snapshot
PD-1: an inhibitory immunoreceptor involved in peripheral tolerance
inferredcites →https://doi.org/10.1034/j.1600-065x.2002.18803.xopenalex-snapshot
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy
inferredcites →https://doi.org/10.1038/35074122openalex-snapshot
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
inferredcites →https://doi.org/10.1038/85330openalex-snapshot
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
inferredcites →https://doi.org/10.1038/86297openalex-snapshot
A fresh look at tumor immunosurveillance and immunotherapy
inferredcites →https://doi.org/10.1038/leu.2009.46openalex-snapshot
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
inferredcites →https://doi.org/10.1038/leu.2010.11openalex-snapshot
Lck is a key target of imatinib and dasatinib in T-cell activation
inferredcites →https://doi.org/10.1038/mt.2009.210openalex-snapshot
Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor Eradication
inferredcites →https://doi.org/10.1038/nature10673openalex-snapshot
Cancer immunotherapy comes of age
inferredcites →https://doi.org/10.1038/ni1102-991openalex-snapshot
Cancer immunoediting: from immunosurveillance to tumor escape
inferredcites →https://doi.org/10.1038/nm.1882openalex-snapshot
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
inferredcites →https://doi.org/10.1038/nm.2438openalex-snapshot
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
inferredcites →https://doi.org/10.1038/nrc1669openalex-snapshot
Cancer/testis antigens, gametogenesis and cancer
inferredcites →https://doi.org/10.1038/nrc1782openalex-snapshot
Paradoxical roles of the immune system during cancer development
inferredcites →https://doi.org/10.1038/nrclinonc.2011.116openalex-snapshot
Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know
inferredcites →https://doi.org/10.1038/sj.bjc.6602500openalex-snapshot
Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma
inferredcites →https://doi.org/10.1038/sj.mt.6300104openalex-snapshot
Adoptive Transfer of Chimeric Antigen Receptor Re-directed Cytolytic T Lymphocyte Clones in Patients with Neuroblastoma
inferredcites →https://doi.org/10.1056/nejmoa1104621openalex-snapshot
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1200690openalex-snapshot
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
inferredcites →https://doi.org/10.1056/nejmoa1302369openalex-snapshot
Nivolumab plus Ipilimumab in Advanced Melanoma
inferredcites →https://doi.org/10.1073/pnas.0708594105openalex-snapshot
Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis
inferredcites →https://doi.org/10.1073/pnas.0813101106openalex-snapshot
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
inferredcites →https://doi.org/10.1073/pnas.86.17.6719openalex-snapshot
Selective changes in expression of HLA class I polymorphic determinants in human solid tumors.
inferredcites →https://doi.org/10.1073/pnas.90.2.720openalex-snapshot
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.
inferredcites →https://doi.org/10.1074/jbc.r700004200openalex-snapshot
The Interferons: 50 Years after Their Discovery, There Is Much More to Learn
inferredcites →https://doi.org/10.1080/02841860510029978openalex-snapshot
Interferon-α as the only adjuvant treatment in high-grade osteosarcoma: Long term results of the Karolinska Hospital series
inferredcites →https://doi.org/10.1084/jem.155.4.1133openalex-snapshot
GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody.
inferredcites →https://doi.org/10.1084/jem.155.6.1823openalex-snapshot
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
inferredcites →https://doi.org/10.1084/jem.192.7.1027openalex-snapshot
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
inferredcites →https://doi.org/10.1084/jem.20020092openalex-snapshot
A Critical Role for Natural Killer T Cells in Immunosurveillance of Methylcholanthrene-induced Sarcomas
inferredcites →https://doi.org/10.1089/1084978042484812openalex-snapshot
Phase I/II Trial of Autologous Tumor Cell Line–Derived Vaccines for Recurrent or Metastatic Sarcomas
inferredcites →https://doi.org/10.1093/annonc/mdi226openalex-snapshot
Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients
inferredcites →https://doi.org/10.1093/oxfordjournals.bmb.a070310openalex-snapshot
IMMUNOLOGICAL FACTORS IN THE PROCESS OF CARCINOGENESIS
inferredcites →https://doi.org/10.1097/00000658-189112000-00015openalex-snapshot
CONTRIBUTION TO THE KNOWLEDGE OF SARCOMA
inferredcites →https://doi.org/10.1097/00000658-198910000-00008openalex-snapshot
Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients
inferredcites →https://doi.org/10.1097/00000658-199905000-00002openalex-snapshot
Pulmonary Metastases From Soft Tissue Sarcoma
inferredcites →https://doi.org/10.1097/00001622-200107000-00010openalex-snapshot
Soft tissue sarcoma as a model disease to examine cancer immunotherapy
inferredcites →https://doi.org/10.1097/00006534-198112000-00122openalex-snapshot
Conservative surgery and postoperative radiotherapy in 300 adults with soft tissue sarcoma
inferredcites →https://doi.org/10.1097/00007890-199560120-00020openalex-snapshot
SARCOMAS IN ORGAN ALLOGRAFT RECIPIENTS1,2
inferredcites →https://doi.org/10.1097/cmr.0b013e328333bbc8openalex-snapshot
Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma
inferredcites →https://doi.org/10.1111/j.1349-7006.2006.00317.xopenalex-snapshot
Prognostic significance of HLA class I expression in osteosarcoma defined by anti‐pan HLA class I monoclonal antibody, EMR8‐5
inferredcites →https://doi.org/10.1111/j.1349-7006.2012.02370.xopenalex-snapshot
SYT ‐ SSX breakpoint peptide vaccines in patients with synovial sarcoma: A study from the J apanese M usculoskeletal O ncology G roup
inferredcites →https://doi.org/10.1111/j.1365-2567.2007.02587.xopenalex-snapshot
Cancer immunoediting from immune surveillance to immune escape
inferredcites →https://doi.org/10.1111/j.1399-3046.2008.01066.xopenalex-snapshot
Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors
inferredcites →https://doi.org/10.1111/j.1749-6632.2009.05122.xopenalex-snapshot
Signaling of c‐kit in dendritic cells influences adaptive immunity
inferredcites →https://doi.org/10.1126/scitranslmed.3005930openalex-snapshot
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
inferredcites →https://doi.org/10.1136/bmj.1.5022.779openalex-snapshot
Cancer--A Biological Approach: I. The Processes Of Control. II. The Significance of Somatic Mutation
inferredcites →https://doi.org/10.1136/gut.28.1.113openalex-snapshot
Computed tomography of the gastrointestinal tract including the peritoneal cavity and mesentery
inferredcites →https://doi.org/10.1136/gut.28.2.113openalex-snapshot
Immunotherapy for cancer: the use of lymphokine activated killer (LAK) cells.
inferredcites →https://doi.org/10.1146/annurev.immunol.23.021704.115839openalex-snapshot
TNF/TNFR FAMILY MEMBERS IN COSTIMULATION OF T CELL RESPONSES
inferredcites →https://doi.org/10.1146/annurev.immunol.25.022106.141609openalex-snapshot
Immunosuppressive Strategies that are Mediated by Tumor Cells
inferredcites →https://doi.org/10.1155/2011/438940openalex-snapshot
Immune-Based Therapies for Sarcoma
inferredcites →https://doi.org/10.1155/2013/168145openalex-snapshot
A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma
inferredcites →https://doi.org/10.1158/0008-5472.can-08-4709openalex-snapshot
The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies
inferredcites →https://doi.org/10.1158/0008-5472.can-13-0371openalex-snapshot
Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors
inferredcites →https://doi.org/10.1158/1078-0432.ccr-040029openalex-snapshot
Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma
inferredcites →https://doi.org/10.1158/1078-0432.ccr-06-1183openalex-snapshot
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-07-4065openalex-snapshot
A Pilot Study of Consolidative Immunotherapy in Patients with High-Risk Pediatric Sarcomas
inferredcites →https://doi.org/10.1158/1078-0432.ccr-09-1624openalex-snapshot
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
inferredcites →https://doi.org/10.1159/000386035openalex-snapshot
The Concept of Immunological Surveillance
inferredcites →https://doi.org/10.1172/jci32136openalex-snapshot
Harnessing the immune system to treat cancer
inferredcites →https://doi.org/10.1182/blood-2005-02-0607openalex-snapshot
CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients
inferredcites →https://doi.org/10.1182/blood-2007-12-128843openalex-snapshot
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
inferredcites →https://doi.org/10.1182/blood-2009-12-256800openalex-snapshot
Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy
inferredcites →https://doi.org/10.1182/blood-2010-01-265041openalex-snapshot
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells
inferredcites →https://doi.org/10.1186/1472-6890-12-5openalex-snapshot
Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas
inferredcites →https://doi.org/10.1186/1479-5876-3-1openalex-snapshot
Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma
inferredcites →https://doi.org/10.1186/1479-5876-6-23openalex-snapshot
Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors
inferredcites →https://doi.org/10.1189/jlb.1107774openalex-snapshot
Immune-mediated dormancy: an equilibrium with cancer
inferredcites →https://doi.org/10.1200/jco.1984.2.6.617openalex-snapshot
Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study.
inferredcites →https://doi.org/10.1200/jco.1999.17.1.150openalex-snapshot
Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study
inferredcites →https://doi.org/10.1200/jco.1999.17.7.2105openalex-snapshot
High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993
inferredcites →https://doi.org/10.1200/jco.2001.19.9.2370openalex-snapshot
High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801
inferredcites →https://doi.org/10.1200/jco.2003.02.026openalex-snapshot
Localized Extremity Soft Tissue Sarcoma: Improved Knowledge With Unchanged Survival Over Time
inferredcites →https://doi.org/10.1200/jco.2006.05.9964openalex-snapshot
Treatment of Metastatic Renal Cell Carcinoma With Autologous T-Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX: First Clinical Experience
inferredcites →https://doi.org/10.1200/jco.2008.14.0095openalex-snapshot
Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group
inferredcites →https://doi.org/10.1200/jco.2010.32.2537openalex-snapshot
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
inferredcites →https://doi.org/10.1200/jco.2013.31.15_suppl.lba10504openalex-snapshot
MAP plus maintenance pegylated interferon α-2b (MAP-IFN) versus MAP alone in patients (pts) with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomization.
inferredcites →https://doi.org/10.1200/jco.2014.60.0734openalex-snapshot
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
inferredcites →https://doi.org/10.1245/aso.2005.03.536openalex-snapshot
Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study
inferredcites →https://doi.org/10.1302/0301-620x.68b5.3782245openalex-snapshot
Spontaneous regression of a desmoid tumour
inferredcites →https://doi.org/10.1371/journal.pone.0014611openalex-snapshot
Prognostic Impact of Lymphocytes in Soft Tissue Sarcomas
inferredcites →https://doi.org/10.1634/theoncologist.2009-0028openalex-snapshot
What Is the Role of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade in Patients with Metastatic Melanoma?
inferredcites →https://doi.org/10.2106/00004623-198668050-00025openalex-snapshot
Acute dislocation of the patella
inferredcites →https://doi.org/10.2147/tcrm.s5688openalex-snapshot
Review of mifamurtide in the treatment of patients with osteosarcoma
inferredcites →https://doi.org/10.3109/02841869509127199openalex-snapshot
Long-Term Adjuvant Interferon Treatment of Human Osteosarcoma: A pilot study
inferredcites →https://doi.org/10.4049/jimmunol.153.12.5422openalex-snapshot
CD27 is a signal-transducing molecule involved in CD45RA+ naive T cell costimulation.
inferredcites →https://doi.org/10.4049/jimmunol.171.11.5931openalex-snapshot
CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination
inferredcites →https://doi.org/10.4049/jimmunol.172.7.3983openalex-snapshot
IL-2, Regulatory T Cells, and Tolerance
inferredcites →https://doi.org/10.4049/jimmunol.173.5.3084openalex-snapshot
Functional Maturation of CD4+CD25+CTLA4+CD45RA+ T Regulatory Cells in Human Neonatal T Cell Responses to Environmental Antigens/Allergens
inferredcites →https://doi.org/10.4049/jimmunol.174.1.90openalex-snapshot
Dendritic Cells Loaded with Stressed Tumor Cells Elicit Long-Lasting Protective Tumor Immunity in Mice Depleted of CD4+CD25+ Regulatory T Cells
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4857103openalex-extracted
A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Cancer
inferred← citeshttps://doi.org/10.1001/jamaoncol.2019.6152openalex-snapshot
Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab
inferred← citeshttps://doi.org/10.1002/cam4.2728openalex-snapshot
Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC‐3G3) to patients with advanced soft tissue sarcoma
inferred← citeshttps://doi.org/10.1007/978-3-319-43121-5_12openalex-snapshot
Chemotherapy and Other Systemic Approaches to Adult Sarcomas
inferred← citeshttps://doi.org/10.1007/978-3-319-43121-5_9openalex-snapshot
Multidisciplinary Approach to Salvage of Unplanned Sarcoma Resections
inferred← citeshttps://doi.org/10.1007/978-3-319-53156-4_2openalex-snapshot
Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy
inferred← citeshttps://doi.org/10.1007/978-3-319-53156-4_6openalex-snapshot
Immune Therapy for Sarcomas
inferred← citeshttps://doi.org/10.1007/s00256-017-2762-yopenalex-snapshot
MRI findings associated with microscopic residual tumor following unplanned excision of soft tissue sarcomas in the extremities
inferred← citeshttps://doi.org/10.1007/s00280-018-3723-4openalex-snapshot
Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma
inferred← citeshttps://doi.org/10.1007/s11864-022-00956-2openalex-snapshot
Role of Virus-Directed Therapy in Soft Tissue Sarcoma
inferred← citeshttps://doi.org/10.1007/s11912-020-00936-5openalex-snapshot
The Evolving Role of Radiation Therapy in Patients with Metastatic Soft Tissue Sarcoma
inferred← citeshttps://doi.org/10.1007/s40272-018-0297-xopenalex-snapshot
Pediatric Cancer Immunotherapy: Opportunities and Challenges
inferred← citeshttps://doi.org/10.1016/b978-0-12-409547-2.12426-6openalex-snapshot
Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1016/b978-0-12-821666-8.00070-0openalex-snapshot
The immune environment of bone sarcomas
inferred← citeshttps://doi.org/10.1016/j.bbcan.2015.05.006openalex-snapshot
The Hippo signal transduction pathway in soft tissue sarcomas
inferred← citeshttps://doi.org/10.1016/j.eclinm.2024.102991openalex-snapshot
Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial
inferred← citeshttps://doi.org/10.1016/j.gene.2020.145105openalex-snapshot
Identification of a survival-related signature for sarcoma patients through integrated transcriptomic and proteomic profiling analyses
inferred← citeshttps://doi.org/10.1016/j.metrad.2024.100069openalex-snapshot
Deep learning-based artificial intelligence for assisting diagnosis, assessment and treatment in soft tissue sarcomas
inferred← citeshttps://doi.org/10.1016/j.thorsurg.2015.09.009openalex-snapshot
Immunotherapy for Resected Pulmonary Metastases
inferred← citeshttps://doi.org/10.1016/j.yexcr.2017.02.005openalex-snapshot
A novel rat fibrosarcoma cell line from transformed bone marrow-derived mesenchymal stem cells with maintained in vitro and in vivo stemness properties
inferred← citeshttps://doi.org/10.1016/s0140-6736(16)30587-6openalex-snapshot
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
inferred← citeshttps://doi.org/10.1017/9781316535097.005openalex-snapshot
Medical Treatment of Adult Soft Tissue Sarcomas and Gastrointestinal Stromal Tumors
inferred← citeshttps://doi.org/10.1080/2162402x.2020.1847846openalex-snapshot
A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
inferred← citeshttps://doi.org/10.1097/cco.0000000000000302openalex-snapshot
Targeted treatments of sarcomas and connective tumors beside gastrointestinal stromal tumor
inferred← citeshttps://doi.org/10.1097/md.0000000000029621openalex-snapshot
PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in cutaneous angiosarcoma: A case report
inferred← citeshttps://doi.org/10.1101/085910openalex-snapshot
Harnessing the lymphocyte meta-phenotype to optimize adoptive cell therapy
inferred← citeshttps://doi.org/10.1101/2025.01.03.631189openalex-snapshot
Transcriptomic Profiling of Old Age Sarcoma Patients using TCGA RNA-seq data
inferred← citeshttps://doi.org/10.1111/vco.12813openalex-snapshot
Developing a translational murine‐to‐canine pathway for an IL ‐2/agonist anti‐CD40 antibody cancer immunotherapy
inferred← citeshttps://doi.org/10.1136/jitc-2019-000271openalex-snapshot
Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes
inferred← citeshttps://doi.org/10.1155/2015/547460openalex-snapshot
Analysis of the Intratumoral Adaptive Immune Response in Well Differentiated and Dedifferentiated Retroperitoneal Liposarcoma
inferred← citeshttps://doi.org/10.1177/1073274818815504openalex-snapshot
The Future of Radiation Oncology in Soft Tissue Sarcoma
inferred← citeshttps://doi.org/10.1186/s12885-018-5163-2openalex-snapshot
The changing landscape of phase II/III metastatic sarcoma clinical trials—analysis of ClinicalTrials.gov
inferred← citeshttps://doi.org/10.1186/s12967-021-02829-yopenalex-snapshot
Is immunotherapy in the future of therapeutic management of sarcomas?
inferred← citeshttps://doi.org/10.1186/s13045-021-01125-yopenalex-snapshot
Metabolic landscapes in sarcomas
inferred← citeshttps://doi.org/10.1186/s13569-016-0053-3openalex-snapshot
Dendritic and mast cell involvement in the inflammatory response to primary malignant bone tumours
inferred← citeshttps://doi.org/10.1186/s40425-015-0067-zopenalex-snapshot
Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma
inferred← citeshttps://doi.org/10.14393/ufu.te.2019.2239openalex-snapshot
Avaliação da atividade citotóxica, antitumoral, mutagênica, recombinogênica e genotóxica do [Cu(Dox)(Phen)]2+
inferred← citeshttps://doi.org/10.15406/mojcsr.2016.03.00065openalex-snapshot
Cancer Immunotherapy: New Technology to Target Cancer Cells
inferred← citeshttps://doi.org/10.1634/theoncologist.2016-0025openalex-snapshot
Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas
inferred← citeshttps://doi.org/10.20517/cdr.2021.88openalex-snapshot
Epigenetic modulation in sensitizing metastatic sarcomas to therapies and overcoming resistance
inferred← citeshttps://doi.org/10.2174/0929867325666181106114421openalex-snapshot
Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules
inferred← citeshttps://doi.org/10.21873/anticanres.12140openalex-snapshot
Radiation Enhances the Efficacy of Antitumor Immunotherapy with an Immunocomplex of Interleukin-2 and its Monoclonal Antibody
inferred← citeshttps://doi.org/10.26508/lsa.202302200openalex-snapshot
The coenzyme A precursor pantethine enhances antitumor immunity in sarcoma
inferred← citeshttps://doi.org/10.26641/1997-9665.2018.2.62-71openalex-snapshot
The investigation of PD-L1 expression as a prognostic marker for uterine sarcoma.
inferred← citeshttps://doi.org/10.29245/2578-2967/2018/2.1127openalex-snapshot
A Review of Osteosarcoma Therapeutics
inferred← citeshttps://doi.org/10.3389/fonc.2015.00181openalex-snapshot
Immunotherapy of Childhood Sarcomas
inferred← citeshttps://doi.org/10.3389/fonc.2026.1751879openalex-snapshot
Pembrolizumab for MSI-high/TMB-high bone and soft tissue sarcomas: a retrospective single-institution study
inferred← citeshttps://doi.org/10.3390/cancers13061317openalex-snapshot
Biological Heterogeneity of Chondrosarcoma: From (Epi) Genetics through Stemness and Deregulated Signaling to Immunophenotype
inferred← citeshttps://doi.org/10.3390/cancers14225675openalex-snapshot
Integrated Analysis of TME and Hypoxia Identifies a Classifier to Predict Prognosis and Therapeutic Biomarkers in Soft Tissue Sarcomas
inferred← citeshttps://doi.org/10.3390/cancers15194871openalex-snapshot
Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas
inferred← citeshttps://doi.org/10.3390/cancers17101706openalex-snapshot
Clinical Differences Among Histological Categories of Sarcoma: Insights from 97,062 Patients
inferred← citeshttps://doi.org/10.3892/ol.2015.3962openalex-snapshot
Strategies and developments of immunotherapies in osteosarcoma
inferred← citeshttps://doi.org/10.4236/crcm.2015.45033openalex-snapshot
Results of Oncothermia Combined with Operation, Chemotherapy and Radiation Therapy for Primary, Recurrent and Metastatic Sarcoma
inferred← citeshttps://doi.org/10.5152/dir.2020.19405openalex-snapshot
Liver-directed treatments of liver-dominant metastatic leiomyosarcoma
inferred← citeshttps://doi.org/10.70675/69d89730z693dz4330za234z5f8e56bde8d7openalex-snapshot
Implication of immune system in chondrosarcoma progression and therapeutic response : Could immunotherapy play a role in chondrosarcoma treatment ?
inferred← citeshttps://doi.org/10.70675/a11f6d3azd770z47bcz8e88z24ce745273a6openalex-snapshot
Projet PériSARC : identification de facteurs morphologiques et moléculaires prédictifs de rechute dans les sarcomes des tissus mous des membres et de la paroi du tronc
inferred← citeshttps://doi.org/10.7759/cureus.1710openalex-snapshot
Somatostatin Receptor Avidity in Gastrointestinal Stromal Tumors: Theranostic Implications of Gallium-68 Scan and Eligibility for Peptide Receptor Radionuclide Therapy
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.